Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of teriparatide acetate cas 52232-67-4 in China. Welcome to wholesale bulk high quality teriparatide acetate cas 52232-67-4 for sale here from our factory. Good service and reasonable price are available.
Teriparatide acetate, also known as parathyroid hormone (1-34) acetate or PTH (1-34) acetate, is a synthetic form of the naturally occurring parathyroid hormone, specifically the first 34 amino acids of the hormone. It is a potent bone-forming agent primarily used in the treatment of osteoporosis, a condition characterized by reduced bone density and increased risk of fractures.
This medication works by stimulating osteoblasts, the cells responsible for bone formation, to increase bone mineral density and strength. It promotes the synthesis of new bone tissue and enhances the remodeling process, leading to improved bone quality. It is administered via daily subcutaneous injection and is typically prescribed for patients with severe osteoporosis or those who have not responded adequately to other therapies.
While it can be an effective treatment option, it is associated with certain risks and side effects, including dizziness, nausea, and leg cramps. Long-term use may also increase the risk of bone cancer (osteosarcoma) in some patients, particularly those with Paget's disease of bone or a prior history of radiation therapy to the skeleton. Therefore, its use is carefully monitored and typically limited to a maximum of two years.
In summary, teriparatide acetate offers a targeted approach to managing osteoporosis by directly stimulating bone growth, but its benefits must be weighed against potential risks and side effects under the guidance of a healthcare professional.
Customized Bottle Caps & Corks
|
|
|
Teriparatide can mediate bone metabolism by inhibiting osteoblast apoptosis, activating bone lining cells and enhancing osteoblast differentiation. It can intermittently stimulate the PHT-Ⅰ receptors on the surface of osteoblasts, bone lining cells and bone marrow stromal stem cells by regulating the adenylate cyclase-cyclic adenosine monophosphate-protein kinase A conduction pathway, promote osteoblast differentiation and prolong osteoblast life; stimulate osteoblast proliferation through the phosphate C-cytoplasmic calcium ion-protein kinase C signaling pathway; reduce the differentiation of stromal cells into adipocytes by inhibiting the transactivation activity of PPARγ, and increase the number of osteoblasts; indirectly regulate bone growth by regulating cytokines, for example, it can induce iGF-1 to bind to osteoblasts, thereby promoting bone formation; regulate the process of bone formation through the Wnt signaling pathway, thereby increasing bone formation.
Teriparatide acetate has multiple uses in the laboratory, mainly related to the research and drug development of osteoporosis. The following are some of the main uses of terlipide acetate in the laboratory:
|
|
|
|
Osteoporosis model construction: In order to better understand the pathogenesis of osteoporosis and find effective treatment methods, researchers often use animal models. Acetate tripeptide can be used to construct these models because it can stimulate bone formation, increase bone density, and simulate some characteristics of osteoporosis. By observing the changes in bones in the model, the effectiveness of different treatment strategies can be evaluated.
Drug screening: Teripaptide acetate can also be used to screen for potential anti osteoporosis drugs. Researchers can use it in conjunction with other candidate drugs to observe their effects on bones and determine which drugs have potential therapeutic effects. This screening method helps to accelerate the development process of new drugs.
Cell culture research: In cell culture, terlipide acetate can be used to study the biological behavior of skeletal cells. For example, it can be used to stimulate or inhibit the growth and function of specific types of bone cells (such as osteoblasts or osteoclasts) to understand their role in osteoporosis.
Protein expression and purification: As a relatively small protein, terlipide acetate can be used as a model system for studying protein expression and purification. Researchers can express terlipide acetate by synthesizing genes and transferring them into appropriate cell lines, and then using various purification techniques to isolate it from other cellular components. This model helps to develop more effective methods for protein production and purification.
Pharmacokinetic studies: In order to better understand the behavior and efficacy of terlipide acetate in vivo, researchers can use animal models for pharmacokinetic studies. By injecting animals with terlipide acetate and measuring its concentration at different time points, the absorption, distribution, metabolism, and excretion characteristics of the drug can be evaluated, providing valuable information for clinical applications.
Biosensor development: Teripaptide acetate can also be used to develop biosensors for detecting molecules related to osteoporosis. By combining terlipide acetate with other molecules, sensors capable of detecting these molecules can be designed. These sensors can be used to study the pathogenesis of osteoporosis, monitor disease progression, or evaluate treatment efficacy.
Protein interaction research: Teripaptide acetate may interact with other proteins, affecting its function in vivo. Researchers can use various techniques to study these interactions, such as immunoprecipitation, mass spectrometry analysis, and fluorescence resonance energy transfer. These studies help to reveal the mechanism of action of terlipide acetate in osteoporosis.
Gene therapy strategy research: In order to treat osteoporosis more effectively, researchers are exploring the use of gene therapy strategies. Acetate tripeptide can serve as a carrier or target for gene therapy, regulating the growth and function of bone cells by introducing genes into them. This research helps to develop more personalized treatment strategies to meet the needs of different patients.
Preclinical trials: Before pushing new drugs into clinical trials, researchers usually conduct preclinical trials. In these experiments, terlipide acetate can be used to evaluate its safety and efficacy in animal models. By comparing the efficacy of different doses and administration methods, the optimal treatment plan can be determined and provide a basis for subsequent clinical trials.
protein purification method
Obtaining the target gene: Firstly, it is necessary to obtain the gene encoding terlipide acetate. This can be achieved through chemical synthesis or extraction from natural sources. The gene sequence can be designed based on known amino acid sequences or cloned from organisms containing tripeptide.
Construction of expression vector: Insert the target gene into an appropriate expression vector, such as a plasmid or viral vector. The expression vector should contain regulatory elements that enable the target gene to be expressed in host cells.
Transforming host cells: Importing the constructed expression vector into appropriate host cells. Host cells can be prokaryotic cells (such as E. coli) or eukaryotic cells (such as yeast or mammalian cells).
Expression of target protein: Under appropriate culture conditions, host cells express the target protein. This step usually involves inducing gene expression signals, such as adding inducers or changing culture conditions.
Cell fragmentation and preliminary separation: Breaking cells through physical or chemical methods to release intracellular proteins. Then, through preliminary separation techniques such as centrifugation and filtration, cell debris and other miscellaneous proteins are removed.
Protein purification: A series of protein purification techniques, such as ion exchange chromatography, gel filtration chromatography, affinity chromatography, etc., are used to purify the target protein. These technologies are based on the physical and chemical properties of proteins for separation.
Generation and transformation of terlipide acetate: During or after purification, the target protein is converted into terlipide acetate. This usually involves chemical or enzymatic reactions to convert the target protein into the final product.
Product quality control: Evaluate and control the quality of terlipide acetate through various analytical methods such as mass spectrometry, chromatography, and biological activity testing. Ensure that the product meets the predetermined quality standards.
Product storage and transportation: Properly store and transport qualified terlipide acetate to ensure product quality is not affected.
Patient-Centered Considerations: Enhancing Adherence and Outcomes
Patient education is critical for optimizing teriparatide's benefits:
● Injection Technique: Pre-filled pens simplify administration, but proper site rotation (abdomen or thigh) minimizes irritation.
● Monitoring: Baseline and periodic BMD, serum calcium, and creatinine tests ensure safety.
● Lifestyle Modifications: Adequate calcium (1,000–1,200 mg/day) and vitamin D (800–1,000 IU/day) intake, weight-bearing exercise, and fall prevention strategies complement pharmacotherapy.
Teriparatide acetate, also known as Forteo, represents a significant milestone in the research and development of treatments for osteoporosis. With the CAS number 99294-94-7, this compound is a recombinant form of parathyroid hormone (PTH), specifically the N-terminal 34 amino acid fragment of human PTH, functioning as a potent PTH1 receptor agonist.
The research journey began with the understanding of the role of parathyroid hormone in bone metabolism. PTH is naturally produced by the parathyroid glands and plays a crucial role in regulating calcium and phosphorus levels in the blood, thereby influencing bone health. Scientists observed that intermittent use of small doses of PTH or its analogs could stimulate osteoblasts, the cells responsible for bone formation, more than osteoclasts, the cells that break down bone. This led to an overall increase in bone mass and improved bone quality.
It was developed as a therapeutic agent to harness this bone-forming potential. It was found to be effective in treating certain forms of osteoporosis, particularly in postmenopausal women with a high risk of fractures. The drug's ability to promote bone formation made it a unique addition to the arsenal of osteoporosis treatments, which typically focus on inhibiting bone resorption.
The development was not without challenges. Preclinical studies in rats revealed a potential risk of increased osteosarcoma, a type of bone cancer, with long-term use. These findings led to regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration of China, to include a black box warning about the risk of osteosarcoma in the drug's labeling. Despite these concerns, it was approved by the FDA in 2002 and introduced in China in 2011, becoming the first and only bone anabolic agent available for the treatment of osteoporosis in China.
The approval marked a significant advancement in osteoporosis therapy, offering patients a new option to increase bone mass and reduce fracture risk. However, due to the potential risk of osteosarcoma, its use is restricted to a single 24-month course in a patient's lifetime.
In conclusion, teriparatide acetate has undergone extensive research and development, leading to its establishment as an effective treatment for osteoporosis. While concerns about its long-term safety persist, its unique mechanism of action and clinical benefits have made it an important option for patients with this condition.
Hot Tags: teriparatide acetate cas 52232-67-4, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, CAS 89508 65 6, 4 5 chloro 1 1 3 1 3 1 quaterphenyl 5 yl dibenzo b d furan, 4-BroMo-9H-carbazole, 2 chlorospiro cyclopenta def phenanthrene 4 9 fluorene , CAS 2252237 87 7, CAS 58164 04 8